VivoSeq
Oncology

Metastatic Colorectal Cancer (mcrc)

4

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Metastatic Colorectal Cancer (mCRC) is an early-stage landscape with 4 programs across 1 company. The most active players are Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

Phase II Study Evaluating the Efficacy of PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05286814·70 enrolled
A Phase 1b/2 Study of Arfolitixorin as Part of 5-fluorouracil-based Treatment Regimens in the First-line Treatment of Metastatic Colorectal Cancer
Recruiting·IIsofol Medical AB·Preclinical·NCT06922383·90 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)